$AMLN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in AMYLIN PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in AMYLIN PHARMACEUTICALS INC. Get notifications about new insider transactions in AMYLIN PHARMACEUTICALS INC for free.
Page: < prev 1 2 3 4 5 6 7 ... 18 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | J | 0.00 | 7,021 | 0 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | H | 44.64 | 12,000 | 535,680 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | H | 41.34 | 12,000 | 496,080 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | H | 31.77 | 12,000 | 381,240 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | J | 27.30 | 20,000 | 546,000 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | J | 22.89 | 12,000 | 274,680 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | J | 21.52 | 20,000 | 430,400 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | J | 19.24 | 12,000 | 230,880 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | J | 16.23 | 12,000 | 194,760 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | J | 13.18 | 20,000 | 263,600 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | J | 11.68 | 20,000 | 233,600 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Sell | J | 31.00 | 20,000 | 620,000 | 0 | 20 K to 0 (-100.00 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Sell | J | 31.00 | 6,675 | 206,925 | 0 | 6.7 K to 0 (-100.00 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Sell | J | 31.00 | 201 | 6,231 | 0 | 201 to 0 (-100.00 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Sell | J | 31.00 | 23,000 | 713,000 | 0 | 23 K to 0 (-100.00 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Sell | J | 31.00 | 98,286 | 3,046,866 | 0 | 98.3 K to 0 (-100.00 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | DENNER ALEXANDER J | Director | Option Exercise | J | 27.30 | 20,000 | 546,000 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | DENNER ALEXANDER J | Director | Option Exercise | J | 21.52 | 20,000 | 430,400 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | DENNER ALEXANDER J | Director | Option Exercise | J | 13.18 | 20,000 | 263,600 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | DENNER ALEXANDER J | Director | Option Exercise | J | 11.26 | 30,000 | 337,800 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | DENNER ALEXANDER J | Director | Sell | J | 31.00 | 1,104 | 34,224 | 0 | 1.1 K to 0 (-100.00 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | DENNER ALEXANDER J | Director | Sell | J | 31.00 | 9,057 | 280,767 | 1,104 | 10.2 K to 1.1 K (-89.13 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Costa Paulo F | Director | Option Exercise | J | 27.30 | 20,000 | 546,000 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Costa Paulo F | Director | Option Exercise | J | 21.52 | 20,000 | 430,400 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Costa Paulo F | Director | Option Exercise | J | 13.18 | 20,000 | 263,600 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Costa Paulo F | Director | Option Exercise | J | 11.26 | 30,000 | 337,800 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Costa Paulo F | Director | Sell | J | 31.00 | 1,067 | 33,077 | 0 | 1.1 K to 0 (-100.00 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | Costa Paulo F | Director | Sell | J | 31.00 | 24,933 | 772,923 | 1,067 | 26 K to 1.1 K (-95.90 %) |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | BEHRENS M KATHLEEN | Director | Option Exercise | J | 27.30 | 20,000 | 546,000 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | BEHRENS M KATHLEEN | Director | Option Exercise | J | 21.52 | 20,000 | 430,400 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | BEHRENS M KATHLEEN | Director | Option Exercise | J | 13.18 | 20,000 | 263,600 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | BEHRENS M KATHLEEN | Director | Option Exercise | J | 11.26 | 30,000 | 337,800 | 0 | |
| Aug 10 2012 | AMLN | AMYLIN PHARMACEUTI ... | BEHRENS M KATHLEEN | Director | Sell | J | 31.00 | 6,000 | 186,000 | 0 | 6 K to 0 (-100.00 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Grant | A | 14.62 | 39 | 570 | 34,207 | 34.2 K to 34.2 K (+0.11 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP, Chief Complianc ... | Grant | A | 14.62 | 823 | 12,032 | 35,426 | 34.6 K to 35.4 K (+2.38 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | Mihalik Vincent P | SVP, Chief Commerci ... | Grant | A | 14.62 | 890 | 13,012 | 39,917 | 39 K to 39.9 K (+2.28 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Option Exercise | M | 11.95 | 13,091 | 156,437 | 0 | |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Option Exercise | M | 11.95 | 7,209 | 86,148 | 0 | |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Payment of Exercise | F | 30.80 | 1,777 | 54,723 | 192,561 | 194.3 K to 192.6 K (-0.91 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Payment of Exercise | F | 30.80 | 2,797 | 86,134 | 194,338 | 197.1 K to 194.3 K (-1.42 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Buy | M | 11.95 | 7,209 | 86,148 | 197,135 | 189.9 K to 197.1 K (+3.80 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Payment of Exercise | F | 30.80 | 3,739 | 115,143 | 189,926 | 193.7 K to 189.9 K (-1.93 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Payment of Exercise | F | 30.80 | 5,079 | 156,408 | 193,665 | 198.7 K to 193.7 K (-2.56 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Buy | M | 11.95 | 13,091 | 156,437 | 198,744 | 185.7 K to 198.7 K (+7.05 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Grant | A | 14.62 | 1,376 | 20,117 | 185,653 | 184.3 K to 185.7 K (+0.75 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Grant | A | 14.62 | 936 | 13,684 | 64,750 | 63.8 K to 64.8 K (+1.47 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Grant | A | 14.62 | 880 | 12,866 | 73,370 | 72.5 K to 73.4 K (+1.21 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | M | 11.95 | 27,582 | 329,605 | 0 | |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | M | 11.95 | 8,418 | 100,595 | 0 | |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Payment of Exercise | F | 30.80 | 2,404 | 74,031 | 97,945 | 100.3 K to 97.9 K (-2.40 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Payment of Exercise | F | 30.80 | 3,266 | 100,576 | 100,349 | 103.6 K to 100.3 K (-3.15 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Buy | M | 11.95 | 8,418 | 100,595 | 103,615 | 95.2 K to 103.6 K (+8.84 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Payment of Exercise | F | 30.80 | 7,879 | 242,634 | 95,197 | 103.1 K to 95.2 K (-7.64 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Payment of Exercise | F | 30.80 | 10,703 | 329,599 | 103,076 | 113.8 K to 103.1 K (-9.41 %) |
| Jul 26 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Buy | M | 11.95 | 27,582 | 329,605 | 113,779 | 86.2 K to 113.8 K (+32.00 %) |
| Jul 03 2012 | AMLN | AMYLIN PHARMACEUTI ... | BECK TERESA | Director | Option Exercise | A | 0.00 | 610 | 0 | 22,594 | |
| Jul 03 2012 | AMLN | AMYLIN PHARMACEUTI ... | SULLIVAN JOSEPH P | Director | Option Exercise | A | 0.00 | 549 | 0 | 26,413 | |
| May 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | GAVIN JAMES R III | Director | Option Exercise | A | 0.00 | 3,000 | 0 | 3,000 | |
| May 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | GAVIN JAMES R III | Director | Sell | D | 0.00 | 3,000 | 0 | 4,580 | 7.6 K to 4.6 K (-39.58 %) |
| May 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | BECK TERESA | Director | Option Exercise | A | 0.00 | 3,000 | 0 | 3,000 | |
| May 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | BECK TERESA | Director | Sell | D | 0.00 | 3,000 | 0 | 8,000 | 11 K to 8 K (-27.27 %) |
| May 18 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Gift | G | 0.00 | 728 | 0 | 86,197 | 86.9 K to 86.2 K (-0.84 %) |
| May 18 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Gift | G | 0.00 | 1,820 | 0 | 86,925 | 88.7 K to 86.9 K (-2.05 %) |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | ADAMS ADRIAN | Director | Option Exercise | A | 27.30 | 20,000 | 546,000 | 20,000 | |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | ADAMS ADRIAN | Director | Grant | A | 0.00 | 3,000 | 0 | 21,000 | 18 K to 21 K (+16.67 %) |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | SULLIVAN JOSEPH P | Director | Option Exercise | A | 27.30 | 20,000 | 546,000 | 20,000 | |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | SULLIVAN JOSEPH P | Director | Grant | A | 0.00 | 3,000 | 0 | 6,000 | 3 K to 6 K (+100.00 %) |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | A | 27.30 | 20,000 | 546,000 | 20,000 | |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Grant | A | 0.00 | 3,000 | 0 | 98,286 | 95.3 K to 98.3 K (+3.15 %) |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | GAVIN JAMES R III | Director | Option Exercise | A | 27.30 | 20,000 | 546,000 | 20,000 | |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | GAVIN JAMES R III | Director | Grant | A | 0.00 | 3,000 | 0 | 7,580 | 4.6 K to 7.6 K (+65.50 %) |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | EASTHAM KARIN | Director | Option Exercise | A | 27.30 | 20,000 | 546,000 | 20,000 | |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | EASTHAM KARIN | Director | Grant | A | 0.00 | 3,000 | 0 | 6,000 | 3 K to 6 K (+100.00 %) |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | DENNER ALEXANDER J | Director | Option Exercise | A | 27.30 | 20,000 | 546,000 | 20,000 | |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | DENNER ALEXANDER J | Director | Grant | A | 0.00 | 3,000 | 0 | 10,161 | 7.2 K to 10.2 K (+41.89 %) |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | Costa Paulo F | Director | Option Exercise | A | 27.30 | 20,000 | 546,000 | 20,000 | |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | Costa Paulo F | Director | Grant | A | 0.00 | 3,000 | 0 | 26,000 | 23 K to 26 K (+13.04 %) |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | BEHRENS M KATHLEEN | Director | Option Exercise | A | 27.30 | 20,000 | 546,000 | 20,000 | |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | BEHRENS M KATHLEEN | Director | Grant | A | 0.00 | 3,000 | 0 | 6,000 | 3 K to 6 K (+100.00 %) |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | BECK TERESA | Director | Option Exercise | A | 27.30 | 20,000 | 546,000 | 20,000 | |
| May 17 2012 | AMLN | AMYLIN PHARMACEUTI ... | BECK TERESA | Director | Grant | A | 0.00 | 3,000 | 0 | 11,000 | 8 K to 11 K (+37.50 %) |
| May 14 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | M | 9.40 | 10,000 | 94,000 | 0 | |
| May 14 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Option Exercise | M | 9.16 | 8,000 | 73,280 | 0 | |
| May 14 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Buy | M | 9.16 | 8,000 | 73,280 | 95,286 | 87.3 K to 95.3 K (+9.17 %) |
| May 14 2012 | AMLN | AMYLIN PHARMACEUTI ... | SKYLER JAY S | Director | Buy | M | 9.40 | 10,000 | 94,000 | 87,286 | 77.3 K to 87.3 K (+12.94 %) |
| Apr 13 2012 | AMLN | AMYLIN PHARMACEUTI ... | SULLIVAN JOSEPH P | Director | Option Exercise | A | 0.00 | 873 | 0 | 25,864 | |
| Apr 13 2012 | AMLN | AMYLIN PHARMACEUTI ... | CLARK PAUL N | Director | Option Exercise | A | 0.00 | 608 | 0 | 7,480 | |
| Apr 13 2012 | AMLN | AMYLIN PHARMACEUTI ... | BECK TERESA | Director | Option Exercise | A | 0.00 | 793 | 0 | 21,984 | |
| Mar 29 2012 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP, Chief Complianc ... | Option Exercise | M | 9.02 | 5,000 | 45,100 | 18,750 | |
| Mar 29 2012 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP, Chief Complianc ... | Sell | S | 25.00 | 3,000 | 75,000 | 34,603 | 37.6 K to 34.6 K (-7.98 %) |
| Mar 29 2012 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP, Chief Complianc ... | Sell | S | 22.83 | 5,000 | 114,150 | 37,603 | 42.6 K to 37.6 K (-11.74 %) |
| Mar 29 2012 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP, Chief Complianc ... | Buy | M | 9.02 | 5,000 | 45,100 | 42,603 | 37.6 K to 42.6 K (+13.30 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | A | 16.02 | 123,758 | 1,982,603 | 123,758 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Option Exercise | A | 16.02 | 6,242 | 99,997 | 6,242 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Grant | A | 0.00 | 1,529 | 0 | 7,974 | 6.4 K to 8 K (+23.72 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Grant | A | 0.00 | 10,000 | 0 | 34,168 | 24.2 K to 34.2 K (+41.38 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP, Chief Complianc ... | Option Exercise | A | 16.02 | 12,198 | 195,412 | 12,198 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP, Chief Complianc ... | Option Exercise | A | 16.02 | 7,802 | 124,988 | 7,802 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP, Chief Complianc ... | Grant | A | 0.00 | 1,529 | 0 | 7,974 | 6.4 K to 8 K (+23.72 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP, Chief Complianc ... | Grant | A | 0.00 | 6,700 | 0 | 37,603 | 30.9 K to 37.6 K (+21.68 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Mihalik Vincent P | SVP, Chief Commerci ... | Option Exercise | A | 16.02 | 42,979 | 688,524 | 42,979 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Mihalik Vincent P | SVP, Chief Commerci ... | Option Exercise | A | 16.02 | 7,021 | 112,476 | 7,021 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Mihalik Vincent P | SVP, Chief Commerci ... | Grant | A | 0.00 | 1,529 | 0 | 4,519 | 3 K to 4.5 K (+51.14 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Mihalik Vincent P | SVP, Chief Commerci ... | Grant | A | 0.00 | 10,000 | 0 | 39,027 | 29 K to 39 K (+34.45 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Marshall Paul | SVP, Operations | Option Exercise | A | 16.02 | 82,447 | 1,320,801 | 82,447 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Marshall Paul | SVP, Operations | Option Exercise | A | 16.02 | 7,553 | 120,999 | 7,553 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Marshall Paul | SVP, Operations | Grant | A | 0.00 | 1,529 | 0 | 7,974 | 6.4 K to 8 K (+23.72 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Marshall Paul | SVP, Operations | Grant | A | 0.00 | 10,000 | 0 | 31,723 | 21.7 K to 31.7 K (+46.03 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Lloyd Marcea Bland | SVP, Chief Administ ... | Option Exercise | A | 16.02 | 101,035 | 1,618,581 | 101,035 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Lloyd Marcea Bland | SVP, Chief Administ ... | Option Exercise | A | 16.02 | 8,965 | 143,619 | 8,965 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Lloyd Marcea Bland | SVP, Chief Administ ... | Grant | A | 0.00 | 1,529 | 0 | 7,974 | 6.4 K to 8 K (+23.72 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Lloyd Marcea Bland | SVP, Chief Administ ... | Grant | A | 0.00 | 10,000 | 0 | 62,469 | 52.5 K to 62.5 K (+19.06 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | LEONHARDT HARRY J | SVP, Legal, Complia ... | Option Exercise | A | 16.02 | 90,448 | 1,448,977 | 90,448 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | LEONHARDT HARRY J | SVP, Legal, Complia ... | Option Exercise | A | 16.02 | 9,552 | 153,023 | 9,552 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | LEONHARDT HARRY J | SVP, Legal, Complia ... | Grant | A | 0.00 | 1,529 | 0 | 7,386 | 5.9 K to 7.4 K (+26.11 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | LEONHARDT HARRY J | SVP, Legal, Complia ... | Grant | A | 0.00 | 15,000 | 0 | 38,705 | 23.7 K to 38.7 K (+63.28 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Option Exercise | A | 16.02 | 42,099 | 674,426 | 42,099 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Option Exercise | A | 16.02 | 7,901 | 126,574 | 7,901 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Grant | A | 0.00 | 1,529 | 0 | 7,974 | 6.4 K to 8 K (+23.72 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Grant | A | 0.00 | 10,000 | 0 | 184,277 | 174.3 K to 184.3 K (+5.74 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | A | 16.02 | 91,621 | 1,467,768 | 91,621 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Option Exercise | A | 16.02 | 8,379 | 134,232 | 8,379 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Grant | A | 0.00 | 1,529 | 0 | 7,974 | 6.4 K to 8 K (+23.72 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Grant | A | 0.00 | 10,000 | 0 | 63,814 | 53.8 K to 63.8 K (+18.58 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | A | 16.02 | 112,207 | 1,797,556 | 112,207 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Option Exercise | A | 16.02 | 7,793 | 124,844 | 7,793 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Grant | A | 0.00 | 1,529 | 0 | 7,974 | 6.4 K to 8 K (+23.72 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Grant | A | 0.00 | 10,000 | 0 | 72,490 | 62.5 K to 72.5 K (+16.00 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | A | 16.02 | 293,758 | 4,706,003 | 293,758 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | A | 16.02 | 6,242 | 99,997 | 6,242 | |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Grant | A | 0.00 | 1,529 | 0 | 7,974 | 6.4 K to 8 K (+23.72 %) |
| Mar 07 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Grant | A | 0.00 | 30,000 | 0 | 88,745 | 58.7 K to 88.7 K (+51.07 %) |
| Mar 02 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Sell | S | 17.11 | 1,231 | 21,062 | 24,168 | 25.4 K to 24.2 K (-4.85 %) |
| Mar 02 2012 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP, Chief Complianc ... | Option Exercise | A | 0.00 | 1,767 | 0 | 11,767 | |
| Mar 02 2012 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP, Chief Complianc ... | Sell | D | 0.00 | 1,767 | 0 | 30,903 | 32.7 K to 30.9 K (-5.41 %) |
| Mar 02 2012 | AMLN | AMYLIN PHARMACEUTI ... | Mihalik Vincent P | SVP, Chief Commerci ... | Sell | S | 17.11 | 1,231 | 21,062 | 29,027 | 30.3 K to 29 K (-4.07 %) |
| Mar 02 2012 | AMLN | AMYLIN PHARMACEUTI ... | Lloyd Marcea Bland | SVP, Chief Administ ... | Sell | S | 17.11 | 1,846 | 31,585 | 52,469 | 54.3 K to 52.5 K (-3.40 %) |
| Mar 02 2012 | AMLN | AMYLIN PHARMACEUTI ... | LEONHARDT HARRY J | SVP, Legal, Complia ... | Sell | S | 17.11 | 1,231 | 21,062 | 23,705 | 24.9 K to 23.7 K (-4.94 %) |
| Mar 02 2012 | AMLN | AMYLIN PHARMACEUTI ... | KOLTERMAN ORVILLE G | SVP, Chief Medical ... | Sell | S | 17.11 | 1,846 | 31,585 | 174,277 | 176.1 K to 174.3 K (-1.05 %) |
| Mar 02 2012 | AMLN | AMYLIN PHARMACEUTI ... | Gergen Mark J | SVP, Corporate Deve ... | Sell | S | 17.11 | 1,846 | 31,585 | 53,814 | 55.7 K to 53.8 K (-3.32 %) |
| Mar 02 2012 | AMLN | AMYLIN PHARMACEUTI ... | FOLETTA MARK G | SVP, Chief Financia ... | Sell | S | 17.11 | 1,846 | 31,585 | 62,490 | 64.3 K to 62.5 K (-2.87 %) |
| Mar 02 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Option Exercise | A | 0.00 | 4,167 | 0 | 137,917 | |
| Mar 02 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Sell | D | 0.00 | 4,167 | 0 | 58,745 | 62.9 K to 58.7 K (-6.62 %) |
| Mar 02 2012 | AMLN | AMYLIN PHARMACEUTI ... | BRADBURY DANIEL | President & Chief E ... | Sell | S | 17.11 | 1,539 | 26,332 | 62,912 | 64.5 K to 62.9 K (-2.39 %) |
| Feb 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Sell | S | 17.03 | 2,519 | 42,899 | 24,597 | 27.1 K to 24.6 K (-9.29 %) |
| Feb 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | Weyer Christian | SVP, Research & Dev ... | Grant | A | 0.00 | 6,700 | 0 | 27,116 | 20.4 K to 27.1 K (+32.82 %) |
| Feb 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | ROWLAND LLOYD A | VP, Chief Complianc ... | Option Exercise | A | 0.00 | 5,000 | 0 | 10,000 | |
| Feb 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | Mihalik Vincent P | SVP, Chief Commerci ... | Sell | S | 17.03 | 7,518 | 128,033 | 29,657 | 37.2 K to 29.7 K (-20.22 %) |
| Feb 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | Mihalik Vincent P | SVP, Chief Commerci ... | Grant | A | 0.00 | 20,000 | 0 | 37,175 | 17.2 K to 37.2 K (+116.45 %) |
| Feb 24 2012 | AMLN | AMYLIN PHARMACEUTI ... | Marshall Paul | SVP, Operations | Sell | S | 17.03 | 5,638 | 96,016 | 21,723 | 27.4 K to 21.7 K (-20.61 %) |